



(12) Translation of
European patent specification

(11) NO/EP 2799070 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/47 (2006.01)
A61K 31/337 (2006.01)
A61K 31/4412 (2006.01)
A61K 31/4745 (2006.01)
A61K 31/513 (2006.01)
A61K 31/517 (2006.01)
A61K 31/53 (2006.01)
A61K 31/7068 (2006.01)
A61K 45/00 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.07.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.02.13
(86)	European Application Nr.	12863476.3
(86)	European Filing Date	2012.12.27
(87)	The European Application's Publication Date	2014.11.05
(30)	Priority	2011.12.28, JP, 2011290125
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Taiho Pharmaceutical Co., Ltd., 1-27 Kandnishiki-cho, Chiyoda-kuTokyo 101-8444, Japan
(72)	Inventor	FUJITA, Hidenori, c/o Taiho Pharmaceutical Co., Ltd.3 Okubo, Tsukuba-shilbaraki 300-2611, Japan KATO, Masanori, c/o Taiho Pharmaceutical Co., Ltd.3 Okubo, Tsukuba-shilbaraki 300-2611, Japan
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	EFFECT POTENTIATOR FOR ANTITUMOR AGENTS
------	-------	--

(56)	References Cited:	WO-A2-2010/093789 WO-A1-2009/125597 US-A1- 2009 226 443 WO-A1-2009/140549 WO-A1-2006/108059 EP-A1- 2 287 155
------	----------------------	---

'EGFR Sayoyaku irreversible EFGR-TKI ya c-Met Sogaizai Nado tonon Heiyo' MEBIO ONCOLOGY vol. 6, no. 1, 2009, pages 23 - 31, XP008174395

CHU SHENG-HUA ET AL: "c-Met antisense oligodeoxynucleotides increase sensitivity of human glioma cells to paclitaxel", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 24, no. 1, 1 July 2010 (2010-07-01), pages 189-194, XP009183704, ISSN: 1791-2431

'HGF/c-Met o Hyoteki to shita Bunshi Chiryoyaku Kaihatsu no Genjo' EXPERIMENTAL MEDICINE vol. 29, no. 2, January 2011, pages 303 - 309, XP008174130

'ASCO Hokoku: Haigan Ryoiki' MOLECULAR TARGETED THERAPY FOR CANCER vol. 8, no. 4, 2010, pages 267 - 270, XP008174122

'c-Met Sogaizai wa Igan Kansaibo-yo SP Saibo no Koganzai Kanjusei o Zokyo suru' JOURNAL OF THE JAPAN SOCIETY FOR CANCER THERAPY vol. 43, no. 2, 01 October 2008, page 390, XP008174092

NISHII TAKAFUMI; YASHIRO MASAKAZU; TANAKA HIROAKI; INOUE TORU; YAMADA NOBUYA; YAMASHITA YOSHITO; ONODA NAOYOSHI; MAEDA KIYOSHI; SA: "c-Met inhibitor might be a promising molecular-targeted molecule against for CPT11-resistant cancer stem cells", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 50, 1 April 2009 (2009-04-01), page 255, XP055182601, ISSN: 0197-016X

'HGF/Met Signal ni yoru EFGR-TK Sogaikyaku Taisei' RESPIRATORY MEDICINE vol. 17, no. 3, 2010, pages 283 - 288, XP008174129

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Antitumorlegemiddel som omfatter en kombinasjon av 4-(2-fluor-4-(3-(2-fenylacetyl)tioureido)fenoksy)-7-metoksy-N-metylkinolin-6-karboksamid eller et farmasøytisk akseptabelt salt derav og et annet antitumormiddel.
2. Antitumorlegemidlet ifølge krav 1, hvori det andre antitumormidlet er et element valgt fra gruppen som består av paklitaksel, gemcitabin, lapatinib, et tegafur-gimeracil-oteracilkaliumkombinasjonslegemiddel, og irinotekan.
3. 4-(2-fluor-4-(3-(2-fenylacetyl)tioureido)fenoksy)-7-metoksy-N-metylkinolin-6-karboksamid eller et farmasøytisk akseptabelt salt derav for anvendelse i potensiering av antitumoreffekten av et annet antitumormiddel.
4. 4-(2-fluor-4-(3-(2-fenylacetyl)tioureido)-fenoksy)-7-metoksy-N-metylkinolin-6-karboksamid eller et farmasøytisk akseptabelt salt derav for anvendelsen ifølge krav 3, hvori det andre antitumormidlet er et element valgt fra gruppen som består av paklitaksel, gemcitabin, lapatinib, et tegafur-gimeracil-oteracilkaliumkombinasjonslegemiddel og irinotekan.
5. 4-(2-fluor-4-(3-(2-fenylacetyl)tioureido)fenoksy)-7-metoksy-N-metylkinolin-6-karboksamid eller et farmasøytisk akseptabelt salt derav for anvendelse ved behandling av en svulst som administreres sammen med et annet antitumormiddel som en enkelt doseringsform eller som separate doseringsformer, hvori det andre antitumormidlet er et element valgt fra gruppen som består av paklitaksel, gemcitabin, lapatinib, et tegafur-gimeracil-oteracil-kaliumkombinasjonslegemiddel, og irinotekan.